Gulf Pharmaceutical Industries P.S.C Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Basel Nimer Ziyadeh
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | 1.9yrs |
CEO ownership | n/a |
Management average tenure | 2.2yrs |
Board average tenure | 4.8yrs |
Recent management updates
Recent updates
Improved Revenues Required Before Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Stock's 26% Jump Looks Justified
Oct 16Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too
Jan 15Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking
Nov 04Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals
Mar 26Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.
Feb 08Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like
Dec 14CEO
Basel Nimer Ziyadeh
1.9yrs
Tenure
Mr. Basel Nimer Ali Ziyadeh is Chief Executive Officer of Gulf Pharmaceutical Industries P.S.C. from February 2023. Mr. Basel was CEO for Tabuk Pharmaceuticals, where he was instrumental in transforming th...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chief Executive Officer | 1.9yrs | no data | no data | |
Chief Financial Officer | less than a year | no data | no data | |
Chief Technical Officer | 2yrs | no data | no data | |
General Counsel & Chief Compliance Officer | 5yrs | no data | no data | |
Marketing Director | 10.8yrs | no data | no data | |
Chief Corporate Development & Strategy Officer | 2.4yrs | no data | no data | |
Chief Human Resources Officer | 5yrs | no data | no data | |
Chief Commercial Officer | less than a year | no data | no data | |
Company Secretary | no data | no data | no data |
2.2yrs
Average Tenure
Experienced Management: JULPHAR's management team is considered experienced (2.2 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Director | 8yrs | no data | no data | |
Vice-Chairman of the Board | 3.4yrs | no data | no data | |
Independent Director | 4.8yrs | no data | no data | |
Director | 1.8yrs | no data | no data | |
Chairman of the Board | 20yrs | no data | no data | |
Director | 6yrs | no data | no data | |
Director | 5yrs | no data | no data | |
Director | 3.4yrs | no data | no data | |
Director | 2.6yrs | no data | no data |
4.8yrs
Average Tenure
Experienced Board: JULPHAR's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/06 21:52 |
End of Day Share Price | 2025/01/06 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gulf Pharmaceutical Industries P.S.C. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
null RESEARCH DEPARTMENT | Prime Research |